Nectar Lifesciences: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Nectar Lifesciences (NECLIFE) filed a disclosure titled "Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company". The company is valued at about ₹199 crore.
What happened
Nectar Lifesciences (NECLIFE) filed a disclosure with the exchanges on 3 October 2026 at 04:15 PM titled "Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company".
Company snapshot
Nectar Lifesciences is a micro-cap company, with a market value of about ₹199 crore.
The stock last traded at ₹10.23, against a 52-week range of ₹9.3–₹22.4 (54.3% below the high).
Before this filing the shares had moved −16.9% over the month and −10.9% over three months. Average daily turnover over the last 20 sessions was about ₹0.14 crore.
Promoters held 51.84% at the end of Q1 FY27. Foreign institutions owned 0.50% and domestic institutions 3.74%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 281 | -63.2 | -2.82 |
| Q2 FY26 | 5 | -176 | -7.84 |
| Q3 FY26 | 0 | 14.3 | 0.64 |
| Q4 FY26 | 0 | -67.9 | -3.38 |
| Q1 FY27 | 0 | -15.4 | -0.79 |
What history shows
BCEIE has no earlier litigation filing from this company on record since May 2026.
Market-wide, 531 litigation filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 35% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.